Last reviewed · How we verify
Matching Placebo for Upadacitinib
This is a placebo control formulation with no active pharmaceutical ingredient, used as a comparator in clinical trials.
At a glance
| Generic name | Matching Placebo for Upadacitinib |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Matching placebos are inert formulations designed to be indistinguishable from the active drug in appearance, taste, and administration route. They serve as the control arm in randomized controlled trials to isolate the true therapeutic effect of the active drug (upadacitinib in this case) from placebo response and natural disease progression.
Approved indications
Common side effects
Key clinical trials
- Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (PHASE3)
- A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis (PHASE3)
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (PHASE3)
- Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (PHASE3)
- A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (PHASE3)
- A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease (PHASE3)
- A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis (PHASE4)
- A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching Placebo for Upadacitinib CI brief — competitive landscape report
- Matching Placebo for Upadacitinib updates RSS · CI watch RSS
- AbbVie portfolio CI